Seattle Genetics, Inc. will unveil its latest earnings on Monday, February 13, 2012. Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.
Seattle Genetics, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for a loss of 30 cents per share, a narrower loss from the year earlier quarter net loss of 34 cents. During the past three months, the average estimate has moved up from a loss of 34 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at a loss of 30 cents during the last month.
Last quarter, the company came in at net loss of 35 cents per share against a mean estimate of a loss of 46 cents per share, beating estimates after missing them in the previous quarter. In the second quarter, it missed forecasts by 6 cents.
Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?
Wall St. Revenue Expectations: On average, analysts predict $39.1 million in revenue this quarter, a rise of more than fourfold from the year ago quarter. Analysts are forecasting total revenue of $83.7 million for the year, a decline of 22.1% from last year’s revenue of $107.5 million.
Analyst Ratings: seven out of 13 analysts surveyed (53.8%) have a buy rating on Seattle Genetics.. This is below the mean analyst rating of 10 competitors, which average 63.1% buy ratings.
A Look Back: In the third quarter, the company’s loss widened to a loss of a $40.7 million (35 cents a share) from a loss of $34.9 million (34 cents) a year earlier, but beat analyst expectations. Revenue rose 29.2% to $20.7 million from $16 million.
A year-over-year revenue increase in the third quarter snapped a streak of three consecutive quarters of revenue declines. Revenue fell 64.6% in the second quarter, 73.8% in the first quarter and 62.6% in the fourth quarter of the last fiscal year.
Stock Price Performance: During November 9, 2011 to February 7, 2012, the stock price had risen $3.27 (20.3%) from $16.09 to $19.36. The stock price saw one of its best stretches over the last year between January 3, 2012 and January 12, 2012 when shares rose for eight-straight days, rising 12.4% (+$2.04) over that span. It saw one of its worst periods between November 11, 2011 and November 18, 2011 when shares fell for six-straight days, falling 7.6% (-$1.25) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories:
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com